Oxidative stress, vascular dysfunction and heart failure

Heart Failure Reviews

Volumn 4, Issue 2, 1999, Pages 133-145

  Bassenge, Eberhard ^a   Fink, Bruno ^a   Schwemmer, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CATALASE; CHEMOKINE; CYTOKINE; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYDRALAZINE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; NEUROPEPTIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDOREDUCTASE; OXYGEN RADICAL; PROBUCOL; REACTIVE OXYGEN METABOLITE; RETINOL; SCAVENGER; SUPEROXIDE; TROLOX C; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

APOPTOSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HEART DILATATION; HEART STRESS; HUMAN; MYOCARDIAL HIBERNATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; REVIEW; STUNNED HEART MUSCLE; VASCULAR DISEASE; VITAMIN BLOOD LEVEL;

EID: 0032857739     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Lohse MJ, Engelhardt S, Danner S, Bohm M. Mechanisms of beta-adrenergic receptor desensitization: From molecular biology to heart failure. Basic Research in Cardiology 1996;91(Suppl 2):29-34.
2. Ping P, Anzai T, Gao M, Hammond HK. Adenylyl cyclase and G protein receptor kinase expression during development of heart failure. Am J Physiol 1997;273:H707-H717.
3. Remme WJ. Prevention of worsening heart failure: Future focus. Eur Heart J 1998;19:B47-B53.
4. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-355.
5. Wei CM, Lehman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89: 1580-1586.
6. Stewart D. Update on endothelin. Can J Cardiol 1998;14(Suppl D):11D-13D.
7. Drexler H, Hayoz D, Münzel T, Just HJ, Zelis R, Brunner HR. Endothelial function in congestive heart failure. Am Heart J 1993;126:761-764.
8. Drexler H. Changes in the peripheral circulation in heart failure. Curr Opin Cardiol 1995;10: 268-273.
9. Wang J, Seyedi N, Xu X-B, Wolin MS, Hintze TH. Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. Am J Physiol Heat Circ 1994;266:H670-H680.
10. Stewart JM, Wang J, Hintze TH. Role of EDRF in the regulation of shear rate in large coronary arteries in conscious dogs. J Mol Cell Cardiol 1994;26:1625-1633.
11. Hayoz D, Drexler H, Münzel T, et al. Flow mediated arterial dilation is abnormal in congestive heart failure. Circulation 1993;87:VII-92-VII-96.
12. Drexler H, Hayoz D, Münzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992;69:1596-1601.
13. Drexler H. Skeletal muscle failure in heart failure. Circulation 1992;85:1621-1623.
14. Mancini DM, Wilson JR, Bolinger L, et al. In vivo magnetic resonance spectroscopy measurement of deoxymyoglobin during exercise in patients with heart failure: Demonstration of abnormal muscle metabolism despite adequate oxygenagion. Circulation 1994;90:500-508.
15. Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996;93:210-214.
16. Devaux B, Scholz D, Hirche A, Klovekorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997;18:470-479.
17. Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-1143.
18. Yoshizumi M, Perella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73:205-209.
19. Aoki N, Siegfried M, Lefer AM. Anti-EDRF effect of tumor necrosis factor in isolated, perfused cat carotid arteries, am J Physiol 1989;256:H1509-H1512.
20. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.
21. Katz SD, Rao R, Berman JW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994;90:12-16.
22. Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28:964-971.
23. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-711.
24. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 1994;105:897-904.
25. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 1996;148:291-300.
26. Ferrari R, Bachetti T, Confortini R. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1479-1486.
27. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation 1995;92:1379-1382.
28. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-1356.
29. Ferrari R, Agnoletti L, Comini L, et al. Oxidative stress during myocardial ischaemia and heart failure. Eur Heart J 1998;19(Suppl B):B2-B11.
30. Winlaw DS, Smythe GA, Keogh AM, Schyvens CG, Spratt PM, Macdonald PS. Increased nitric oxide production in heart failure. Lancet 1994;344:373-374.
31. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996;347:1151-1155.
32. Haywood GA, Tsao PS, von dLE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996;93:1087-1094.
33. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite-implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-1624.
34. Buttery LD, Springall DR, Chester AH, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996;75:77-85.
35. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148.
36. Fukui T, Ishizaka N, Rajagopalan S, et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997;80:45-51.
37. De KGW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 1998;329:653-657.
38. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chemi 1998;273:15022-15029.
39. Darley-Usmar VM, Wiseman H, Halliwell B. Nitric oxide and oxygen radicals: A question of balance. FEBS Lett 1995;369:131-135.
40. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996;28:506-514.
41. Hill MF, Singal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. Circulation 1997;96:2414-2420.
42. Dhalla AK, Singal PK. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am J Physiol 1994;266:H1280-H1285.
43. Singh N, Dhalla AK, Seneviratne C, Singal PK. Oxidative stress and heart failure. Mol Cell Biochem 1995;147:77-81.
44. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, Hernandez-Lopez E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 1996;131:146-152.
45. Belch JJF, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 1991;655-248.
46. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-isoprostaglandin F2alpha in pericardial fluid of patients with heart failure: A potential role for in vivo oxidants stress in ventricular dilatation and progression to heart failure. Circulation 1998;97:1536-1539.
47. Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;97:363-368.
48. Dikalov S, Fink B, Skatchkov M, Bassenge E. Comparison of glyceryl trinitrate-induced with pentaerythrityl tetranitrate-induced in vivo formation of suproxide radicals: Effect of Vitamin C. Free Radical. Biol. Med. 1999;27(1/2): 169-175.
49. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. J Clin Invest 1995;95:187-194.
50. Dikalov S, Fink B, Skatchkov M, Bassenge E. Formation of reactive oxygen species by PETN and GTN in vitro and development of nitrate tolerance. J Pharmacol Exp Ther 1998;286:938-944.
51. Johnson C, Stubley-Beedham C, Stell JGP. Hydralazine: A potent inhibitor of aldehyde oxidase activity in vitro and in vivo. Biochem Pharmacol 1985;34:4251-4256.
52. Atwal KS. Pharmacology and structure-activity relationships for KATP modulators: Tissue-selective KATP openers. J Cardiovasc Pharmacol 1994;24(Suppl 4):S12-S17.
53. Dikalov S, Skatchkov M, Fink B, Sommer O, Bassenge E. Formation of reactive oxygen species in various vascular cells during glyceryltrinate metabolism. J Cardiovasc Pharmacol Ther 1998;3:51-62.
54. Dikalov S, Kirilyuk I, Grigor'ev I. Spin trapping of O-, C-, and S-centered radicals and peroxynitrite by 2H-imidazole-1-oxides. Biochem Biophys Res Commun 1996;218:616-622.
55. Fink B, Bassenge E. Unexpected, tolerance-devoid vasomotor and platelet actions of pentaerytrityl tetranitrate. J Cardiovasc Pharmacol 1997;30:831-836.
56. Kojda G, Stein D, Kottenberg E, Schnaith EM, Noack E. In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1995;25:763-773.
57. Szabo C, Zingarelli B, Salzman AL. Role of poly-ADP ribosyltransferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite. Cir Res 1996;78:1051-1063.
58. Nossuli TO, Hayward R, Jensen D, Scalia R, Lefer AM. Mechanisms of cardioprotection by peroxynitrite in myocardial ischemia and reperfusion injury. Am J Physiol 1998;275:H509-H519.
59. Bachmaier K, Neu N, Pummerer C, et al. iNOS expression and nitrotyrosine formation in the myocardium in response to inflammation is controlled by the interferon regulatory transcription factor 1. Circulation 1997;96:585-591.
60. Liu P, Hock CE, Nagele R, Wong PY. Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury in rats. Am J Physiol 1997;272:H2327-H2336.
61. Skatchkov M, Larina L, Larin A, Fink N, Bassenge E. Urinary nitrotyrosine content as a marker of peroxynitrite-induced tolerance to organic nitrates. J Cardiovasc Pharmacol Ther 1997;2:85-96.
62. Bassenge E, Fink B. Tolerance to nitrates and simultaneous upregulation of platelet activity prevented by enhancing antioxidant state. Naunyn-Schmiedeberg's Arch Pharmacol 1996;353:363-367.
63. Münzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 1996;98:1465-1470.
64. Schwemmer M, Bassenge E. Substantially altered gene expression in platelets during non-intermittent glyceryl trinitrate. 2 Int Congress, Coronary Artery Disease 1998; 15(Abstract)
65. Braughler JM. Soluble guanylate cyclase activation by nitric oxide and its reversal. Involvement of sulfhydryl group oxidation and reduction. Biochem Pharmacol 1983;32:811-818.
66. Shen W, Lundborg M, Wang J, et al. Role of EDRF in the regulation of regional blood flow and vascular resistance at rest and during exercise in conscious dogs. J Appl Physiol 1994;77:165-172.
67. Singh RB, Niaz MA, Rastogi SS, Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3). Am J Cardiol 1996;77:232-236.
68. Ghatak A, Brar MJ, Agarwal A, et al. Oxy free radical system in heart failure and therapeutic role of oral vitamin E. Int J Cardiol 1996;57:119-127.
69. Ito K, Akita H, Kanazawa K, et al. Comparison of effects of ascorbic acid on endothelium-dependent vasodilation in patients with chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy versus patients with effort angina pectoris secondary to coronary artery disease. Am J Cardiol 1998;82:762-767.
70. Heitzer T, Just HJ, Münzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996;94:6-9.
71. Feuerstein G, Yue TL, Ma X, Ruffolo RR. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol. [Review] [35 refs]. Prog Cardiovasc Dis 1998;48:17-24.
72. Iliskovic N, Singal PK. Lipid lowering: An important factor in preventing adriamycin-induced heart failure. Am J Pathol 1997;150:727-734.
73. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-1191.
74. Khaper N, Singal PK. Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats. J Am Coll Cardiol 1997;29:856-861.
75. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993;14:205-212.
76. Trip MD, Cats VM, van CFJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Eng J Med 1990;322:1549-1554.
77. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986;2:533-537.
78. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI94-101.
79. Bassenge E, Fink N, Skatchkov M, Fink B. Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest 1998;102:67-71.